The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Inclusion Criteria: * 18 years of age at enrollment * Confirmed diagnosed with RA * Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site Exclusion Criteria: * Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels * Was followed at the site for less than 1 year since biologic treatment initiation * Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula Other protocol defined inclusion/exclusion criteria could apply